Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
R&D

CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity

Fineline Cube Dec 28, 2022

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA

Fineline Cube Dec 28, 2022

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for...

Company Drug

Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review

Fineline Cube Dec 28, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone...

Policy / Regulatory

China Downgrades COVID-19 from Class A to Class B Infectious Disease

Fineline Cube Dec 28, 2022

The National Health Commission (NHC) has issued a notice downgrading COVID-19 from a Class A...

Company Deals

Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round

Fineline Cube Dec 28, 2022

Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised...

Company

Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site

Fineline Cube Dec 28, 2022

China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first...

Company Drug

InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL

Fineline Cube Dec 28, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...

Company Deals

LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round

Fineline Cube Dec 28, 2022

LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to...

Company Drug

Simcere Receives NMPA Clearance for SIM0237 Clinical Study

Fineline Cube Dec 28, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Drug

CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website

Fineline Cube Dec 28, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...

Company Deals

Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment

Fineline Cube Dec 28, 2022

Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...

Company Medical Device

BGI Genomics Receives ANVISA Approval for Colorectal Cancer Detection Kit

Fineline Cube Dec 28, 2022

China-based genomics giant BGI Genomics Co., Ltd (SHE: 300676) has reported receiving product approval from...

Company Deals

InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China

Fineline Cube Dec 28, 2022

Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...

Company Drug

Elpiscience Receives IND Approval for ES014 in China

Fineline Cube Dec 27, 2022

Shanghai-based Elpiscience Biopharmaceuticals Inc. has announced receiving Investigational New Drug (IND) approval in China to...

Company Deals

Ablaze Pharma and Yonghe Partner for Targeted Radiotherapy Development

Fineline Cube Dec 27, 2022

China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and...

Company Drug

InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA

Fineline Cube Dec 27, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...

Company Drug

Hainan Poly Pharm Receives FDA Approval for Generic Lincomycin

Fineline Cube Dec 27, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation

Fineline Cube Dec 27, 2022

China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...

Policy / Regulatory

Sichuan Healthcare Security Administration Announces VBP for Oral Implant Systems

Fineline Cube Dec 27, 2022

The Sichuan Provincial Healthcare Security Administration has released a notification regarding the inter-provincial alliance volume-based...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay

Fineline Cube Dec 27, 2022

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...

Posts pagination

1 … 620 621 622 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.